A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

Conditions: TNBC – Triple-Negative Breast Cancer; Ovarian Cancer
Interventions: Drug: Etrumadenant; Drug: IPI-549; Drug: Pegylated liposomal doxorubicin (PLD); Drug: nanoparticle albumin-bound paclitaxel (NP)
Sponsors: Arcus Biosciences, Inc.; Infinity Pharmaceuticals, Inc.
Completed

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 25, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments